Hematological malignancies

Researchers are testing an experimental cell therapy called CHT101 in adults with T-cell or B-cell blood cancers that have returned or stopped responding to treatment. CHT101 uses donor-derived T cells engineered to recognize CD70, a marker found on these cancer cells. The phase …

Researchers are testing CHT101, an experimental CAR-T cell therapy made from donor cells, in adults with T-cell or B-cell blood cancers that have come back or stopped responding to treatment. The therapy targets CD70, a marker found on these cancer cells. The Phase I trial aims t…

This Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…

This study compares luspatercept to epoetin for patients with blood cancers who have poor red blood cell recovery after a stem cell transplant. About 90 adults will receive either drug every three weeks for 24 weeks. The goal is to see which treatment better reduces the need for …

This phase 3 trial tests whether acalabrutinib (a BTK inhibitor) alone or with bortezomib can lower harmful HLA antibodies that cause platelet transfusions to fail in blood cancer patients. About 42 adults with platelet transfusion refractoriness and high antibody levels will be …

This study tests whether the drug luspatercept can prevent severe anemia (low red blood cells) after a stem cell transplant in people with blood cancers and a bone marrow condition called myelofibrosis. About 196 adults will receive either luspatercept or standard supportive care…

This early-phase trial tests a new type of CAR-T therapy for B-cell blood cancers like lymphoma and leukemia. Instead of removing a patient's immune cells, modifying them in a lab, and infusing them back, this drug delivers genetic instructions directly into the body using tiny f…

This early-phase trial tests a new mRNA-based drug called WGb-0302 in 20 adults with recurrent or treatment-resistant multiple myeloma and other blood cancers. The therapy uses lipid nanoparticles to deliver mRNA that targets BCMA, a protein on cancer cells. The main goals are to…

This study is testing whether a blood test called metagenomic next-generation sequencing (mNGS) can accurately diagnose invasive fungal disease in people with blood cancers. These patients are at high risk for such infections, which are often hard to detect and can become severe.…

This study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…

This study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal …

This study looks at how people with blood cancers (like leukemia, lymphoma, or myeloma) in France use complementary and alternative medicines (CAM), such as acupuncture or herbal remedies. Researchers will survey 85 patients and interview some to understand why they use these the…